Unknown

Dataset Information

0

The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.


ABSTRACT:

Purpose

Irinotecan and topotecan are used to treat a variety of different cancers. However, they have limitations, including chemical instability and severe side effects. To overcome these limitations, we developed the clinical indenoisoquinolines: LMP400 (indotecan), LMP776 (indimitecan), and LMP744. The purpose of the study is to build the molecular rationale for phase II clinical trials.

Experimental design

CellMinerCDB (http://discover.nci.nih.gov/cellminercdb) was used to mine the cancer cell lines genomic databases. The causality of Schlafen11 (SLFN11) was validated in isogenic cell lines. Because topoisomerase I (TOP1)-mediated replication DNA damage is repaired by homologous recombination (HR), we tested the "synthetic lethality" of HR-deficient (HRD) cells. Survival and cell-cycle alterations were performed after drug treatments in isogenic DT40, DLD1, and OVCAR cell lines with BRCA1, BRCA2, or PALB2 deficiencies and in organoids cultured from prostate cancer patient-derived xenografts with BRCA2 loss. We also used an ovarian orthotopic allograft model with BRCA1 loss to validate the efficacy of LMP400 and olaparib combination.

Results

CellMinerCDB reveals that SLFN11, which kills cells undergoing replicative stress, is a dominant drug determinant to the clinical indenoisoquinolines. In addition, BRCA1-, BRCA2-, and PALB2-deficient cells were hypersensitive to the indenoisoquinolines. All 3 clinical indenoisoquinolines were also synergistic with olaparib, especially in the HRD cells. The synergy between LMP400 and olaparib was confirmed in the orthotopic allograft model harboring BRCA1 loss.

Conclusions

Our results provide a rationale for molecularly designed clinical trials with the indenoisoquinolines as single agents and in combination with PARP inhibitors in HRD cancers expressing SLFN11.

SUBMITTER: Marzi L 

PROVIDER: S-EPMC6801079 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.

Marzi Laetitia L   Szabova Ludmila L   Gordon Melanie M   Weaver Ohler Zoe Z   Sharan Shyam K SK   Beshiri Michael L ML   Etemadi Moudjib M   Murai Junko J   Kelly Kathleen K   Pommier Yves Y  

Clinical cancer research : an official journal of the American Association for Cancer Research 20190813 20


<h4>Purpose</h4>Irinotecan and topotecan are used to treat a variety of different cancers. However, they have limitations, including chemical instability and severe side effects. To overcome these limitations, we developed the clinical indenoisoquinolines: LMP400 (indotecan), LMP776 (indimitecan), and LMP744. The purpose of the study is to build the molecular rationale for phase II clinical trials.<h4>Experimental design</h4>CellMinerCDB (http://discover.nci.nih.gov/cellminercdb) was used to min  ...[more]

Similar Datasets

| 2401742 | ecrin-mdr-crc
| S-EPMC10244121 | biostudies-literature
| S-EPMC8224818 | biostudies-literature
| S-EPMC7415565 | biostudies-literature
| S-EPMC5031537 | biostudies-literature
| S-EPMC6088797 | biostudies-literature
| S-EPMC11651736 | biostudies-literature
| S-EPMC4415602 | biostudies-literature
| S-EPMC9994488 | biostudies-literature
| S-EPMC9071396 | biostudies-literature